| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 422.3 | 619.1 | 549.3 |
| Other income | 12.2 | 0.0 | 14.2 |
| Total income | 434.5 | 617.3 | 563.5 |
| Profit before exceptional items & tax | -42.9 | 36.4 | 70.9 |
| Exceptional items | 0.0 | 16.5 | 8.1 |
| Profit before tax | -42.9 | 19.9 | 62.8 |
| Net profit | -45.2 | 8.3 | 46.4 |
| Operating margin | -9.9% | 3.2% | 11.1% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | -23.10% |
|---|---|
| Operating profit, year on year | -197.20% |
| Operating profit, quarter on quarter | -251.40% |
NSE results filing, NSE: COHANCE. Figures extracted from the filing.
Cohance Lifesciences Ltd: key numbers
- Share price
- ₹459.25
- Market cap
- ₹17,571 Cr
- Revenue (annual)
- ₹2,269 Cr
- Net profit (annual)
- ₹179.2 Cr
- P/E (TTM)
- 165.4×Sector 50.4×
- Promoter holding
- 57.49%+0.00% QoQ
- FII holding
- 6.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Cohance Lifesciences Ltd
All →Cohance Lifesciences Business Update
Cohance Lifesciences completed a USFDA inspection at its Jaggaiahpet API facility, receiving a Form 483 with five observations. The company has initiated corrective and preventive actions.
Cohance Lifesciences Merger & Restructuring Worth ₹95 Cr
Cohance Lifesciences invested USD 10 million (₹95 Crore) into its subsidiary NJ Bio, Inc. to subscribe for new Compulsorily Convertible Preferred Stock.
- Value
- ₹95.00 Cr
Cohance Lifesciences Annual General Meeting
Cohance Lifesciences Limited conducted its 8th Annual General Meeting on 17 September 2026. All resolutions proposed in the notice were passed by the requisite majority.
Cohance Lifesciences Business Update
Cohance Lifesciences completed a USFDA inspection of its Shamshabad formulation plant, receiving a Form 483 with four observations. The company is initiating corrective measures.
Cohance Lifesciences Acquisition Worth ₹169.2 Cr
Cohance Lifesciences announced a $18 million investment across two subsidiaries, NJ Bio and Aruka Bio, to strengthen its ADC strategy and commercial integration.
- Value
- ₹169.2 Cr
Cohance Lifesciences Earnings Call Transcript: Key Takeaways
Cohance reported its lowest-ever quarter, plagued by customer shipment phasing and biotech funding delays, resulting in a 23% revenue decline. Management frames this as a trough, banking on H2 recovery through restocked commercial molecules.